Last updated on February 2019

A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Brief description of study

This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.


Clinical Study Identifier: TX218034

Find a site near you

Start Over

Neurotrials Research, Inc.

110 Johnson Ferry Road NE Atlanta, GA United States
  Connect »